Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Óscar Rodríguez Faba

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
The Urologic Clinics of North America|November 24, 2019
Salvage Therapies for Non-muscle-invasive Bladder Cancer: Who Will Respond to Bacillus Calmette-Guérin? Predictors and NomogramsÓscar Rodríguez Faba, Francesca Pisano, Wojciech Krajewski, et al.
Archivos Espanoles De Urologia|December 3, 2020
[BCG Immunotherapy, past, present and future.]Óscar Rodríguez Faba, Jorge Huguet Pérez, Francesca Pisano, et al.
Current Opinion in Urology|April 3, 2020
Carcinoma in situ of the bladder: why is it underdetected?José D Subiela, Óscar Rodríguez Faba, Félix Guerrero-Ramos, et al.
Urologic Oncology|April 17, 2021
Endoscopic exploration directly impacts clinical decision making in the management of patients with suspected upper tract urothelial carcinoma following radical cystectomyJúlia Aumatell, Jorge Huguet, José Daniel Subiela, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Predicting Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer: Systematic Review on the Performance of Risk Stratification ModelsFélix Guerrero-Ramos, José Daniel Subiela, Óscar Rodríguez-Faba, et al.
Clinical Genitourinary Cancer|April 19, 2023
Sequential Treatment With Bacillus Calmette-Güerin (BCG) and Mitomycin C Administered With Electromotive Drug Administration (EMDA) in Patients With High-Risk Nonmuscle Invasive Bladder Cancer After BCG FailureIsabel Sanz Gómez, Jorge Huguet, Alejandra Bravo, et al.
BJU International|August 10, 2021
Contemporary outcomes of bladder carcinoma in situ treated with an adequate bacille Calmette-Guérin immunotherapyJosé Daniel Subiela, Óscar Rodríguez Faba, Júlia Aumatell, et al.
Urologic Oncology|June 18, 2021
Impact of clinical and pathological subtypes of carcinoma in situ (CIS) of the bladder: Lessons learned from long-term follow-up of a series of CIS patients treated with BCGJosé Daniel Subiela, Óscar Rodríguez Faba, Julia Aumatell, et al.
Archivos Espanoles De Urologia|October 4, 2019
[Ultrasound-guided cryotherapy of small renal masses: Systematic review.]José Daniel Subiela, Asier Mercadé, Josep Balañà, et al.
Urologic Oncology|June 25, 2021
Non-muscle-invasive bladder cancer: An overview of potential new treatment optionsNeal D Shore, Joan Palou Redorta, Gregoire Robert, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
The Urologic Clinics of North America|November 24, 2019
Salvage Therapies for Non-muscle-invasive Bladder Cancer: Who Will Respond to Bacillus Calmette-Guérin? Predictors and NomogramsÓscar Rodríguez Faba, Francesca Pisano, Wojciech Krajewski, et al.
Archivos Espanoles De Urologia|December 3, 2020
[BCG Immunotherapy, past, present and future.]Óscar Rodríguez Faba, Jorge Huguet Pérez, Francesca Pisano, et al.
Current Opinion in Urology|April 3, 2020
Carcinoma in situ of the bladder: why is it underdetected?José D Subiela, Óscar Rodríguez Faba, Félix Guerrero-Ramos, et al.
Urologic Oncology|April 17, 2021
Endoscopic exploration directly impacts clinical decision making in the management of patients with suspected upper tract urothelial carcinoma following radical cystectomyJúlia Aumatell, Jorge Huguet, José Daniel Subiela, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Predicting Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer: Systematic Review on the Performance of Risk Stratification ModelsFélix Guerrero-Ramos, José Daniel Subiela, Óscar Rodríguez-Faba, et al.
Clinical Genitourinary Cancer|April 19, 2023
Sequential Treatment With Bacillus Calmette-Güerin (BCG) and Mitomycin C Administered With Electromotive Drug Administration (EMDA) in Patients With High-Risk Nonmuscle Invasive Bladder Cancer After BCG FailureIsabel Sanz Gómez, Jorge Huguet, Alejandra Bravo, et al.
BJU International|August 10, 2021
Contemporary outcomes of bladder carcinoma in situ treated with an adequate bacille Calmette-Guérin immunotherapyJosé Daniel Subiela, Óscar Rodríguez Faba, Júlia Aumatell, et al.
Urologic Oncology|June 18, 2021
Impact of clinical and pathological subtypes of carcinoma in situ (CIS) of the bladder: Lessons learned from long-term follow-up of a series of CIS patients treated with BCGJosé Daniel Subiela, Óscar Rodríguez Faba, Julia Aumatell, et al.
Archivos Espanoles De Urologia|October 4, 2019
[Ultrasound-guided cryotherapy of small renal masses: Systematic review.]José Daniel Subiela, Asier Mercadé, Josep Balañà, et al.
Urologic Oncology|June 25, 2021
Non-muscle-invasive bladder cancer: An overview of potential new treatment optionsNeal D Shore, Joan Palou Redorta, Gregoire Robert, et al.
Pageof 2